BEAT

Publication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk Study advances the scientific foundation supporting HeartBeam's planned indication expansion into heart attack detection Large market potential with over 20 million patients in the U.S. at risk of a heart attack HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a peer-reviewed article in JACC: Advances, a journal of the American College of Cardiology, demonstrating that a risk prediction algorithm incorpor

10-Q - HeartBeam, Inc. (0001779372) (Filer)

Signed First Commercial Partners in Leading Concierge Practices ClearCardio™ and Atelier Health Established Flagship Commercial Sites Across New York, Dallas, South Florida and Southern California Strategic Collaboration with Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms, Starting with Heart Attack Detection Strengthened Balance Sheet with $11.5 Million Public Offering Including Full Exercise of Over-Allotment Option Initiated Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Initiated Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic Management to Host Webcast and Conference Call Today

Ambulatory patch device designed to aid in detecting ischemia and complex arrythmias Targets a $2 billion market with established reimbursement; ischemia detection has potential to disrupt the patch market which is currently limited to atrial fibrillation detection HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced the initiation of a pilot study evaluating its novel on-demand 12-lead ECG patch in patients with suspected coronary artery disease. The study is being conducted at two leading hospitals in Belgrade, Serbia. The initiation of the pilot study represents a significant step in the

Leading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patients Opens up flagship sites across New York, Dallas, South Florida and Southern California, supporting scalable expansion of HeartBeam technology in preventive cardiology HeartBeam continues to execute on its go-to-market strategy in high-value, direct-pay care environments HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with Atelier Health, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medic

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answe

4/A - HeartBeam, Inc. (0001779372) (Issuer)

D. Boral Capital downgraded HeartBeam from Buy to Hold

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

8-K - HeartBeam, Inc. (0001779372) (Filer)

Offering was led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it has closed its underwritten public offering of 12,500,000 shares of common stock for total gross proceeds of $10 million before deducting underwriting discounts, commissions, and offering expenses. The closing of the offering occurred on April 16, 2026. The offering was led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing i

424B5 - HeartBeam, Inc. (0001779372) (Filer)

Offering is being led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, le

424B5 - HeartBeam, Inc. (0001779372) (Filer)

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). All of the securities to be sold in the proposed offering will be offered by HeartBeam. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system,

B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit